Okay, so. I’ve had approximately four hundred DMs from friends, cousins, and one very persistent guy from my gym asking the same question in slightly different outfits: “wait, is the semaglutide thing still a thing? Like legally?” And every time I try to answer in one sentence, I fail, because there isn’t one sentence. There’s a whole little saga here, and most of what’s floating around online is describing 2024, not 2026. Grab a coffee. Let’s actually work through this.
The quick version, for the scrollers
Compounded semaglutide isn’t a flat-out crime, but it’s also not FDA-approved, and honestly, it’s not the free-for-all it was a couple years back. Whether a specific compounded batch is okay right now comes down to an individual clinical reason for it, because the broad “everyone can have it, supply is tight” allowance ended once the FDA said the semaglutide shortage was over, back in February 2025 [1].
I want you to sit with that for a second, because three different ideas are hiding in there. “Not illegal” does not mean “approved.” “Okay in specific situations” does not mean “as easy to get as it was in 2024.” Something genuinely shifted, and a shocking amount of content on the internet just… didn’t get the memo.
Wait, what does “compounded” actually mean?
Here’s the plain-English version: compounding is when a pharmacy custom-builds a medication for one specific patient instead of handing you the mass-produced, FDA-approved version off the shelf. Think of a pharmacist as more of a tailor than a factory line, in certain situations.
This is a real, legitimate, long-standing practice, usually discussed under section 503A of the Federal Food, Drug, and Cosmetic Act. Maybe you’re allergic to a dye in the regular pill. Maybe you can’t swallow pills at all and need a liquid. Maybe the exact strength you need isn’t sold commercially. Compounding exists to fill those individual gaps, prescription by prescription, need by need.
And that’s exactly the lens you have to look at compounded semaglutide through now. A compounded drug, by definition, is not the FDA-reviewed finished product. The FDA doesn’t check each individual compounded batch for safety, effectiveness, or quality the way it does before a name-brand drug ever hits a pharmacy shelf [2]. It’s a recognized category, just a different one, and that difference is basically the whole ballgame here.
So how did compounded semaglutide get so huge in the first place?
There was an actual, official shortage. And a real shortage opens a real, legal door for compounding.
When the FDA puts a drug on its shortage list, compounding pharmacies are generally allowed to step in and make versions of it, to help cover demand the brand-name manufacturer can’t. Semaglutide sat on that shortage list for a good while as Wegovy and Ozempic just couldn’t keep up with everyone who wanted them. That’s the window where compounded semaglutide exploded, and honestly, most of the telehealth world you remember from 2023 and 2024 grew up living inside that shortage loophole.
I think it’s worth saying this plainly: that’s not some sketchy back-alley origin story. It came from a real, recognized mechanism tied to a real shortage. The catch is that the mechanism only works while the shortage exists. And it stopped existing.
Here’s the part everyone’s still missing: the shortage ended
This is the one fact you actually need to walk away with today. The FDA declared the semaglutide shortage resolved in February 2025, and the second a drug comes off that list, the broad “shortage justifies mass compounding” logic evaporates with it [1].
I keep coming back to this because it’s the single biggest thing separating “2026 reality” from “2024 vibes.” Once the shortage ended, the easy justification that let pharmacies churn out compounded semaglutide at scale simply doesn’t apply anymore. The FDA has been pretty blunt about its concerns with unapproved and compounded GLP-1 products, pointing out they’re not reviewed for safety, effectiveness, or quality, and flagging real problems like counterfeits and mislabeled products [1].
But, and this is important, patient-specific compounding for a genuine individual medical reason doesn’t just disappear. The shortage was one road into compounding, not the only theoretically possible one. A clinician can still decide a particular patient has a real, individual clinical reason a compounded version makes sense. That’s a narrower, one-person-at-a-time call, not a “supply’s a little tight for everybody, help yourselves” situation. That shift, from mass shortage-driven compounding to individualized, clinician-justified compounding, is basically the whole story of how this year is different from two years ago.
See also: Platform-Based Business Models Explained
Okay but seriously, yes or no: is it legal right now?
I know, I know, you wanted a one-word answer. I can’t give you one honestly, and anyone who does is skipping steps.
Here’s my attempt at the cleanest possible breakdown:
- FDA approval belongs to Wegovy and Ozempic. Not to compounded versions [2].
- It’s not banned outright either. Compounding is a legitimate pharmacy practice, and a patient-specific, prescription-based preparation for a real clinical need is a completely different animal from something counterfeit or illegal.
- The shortage-fueled free-for-all is done. Since the FDA called the shortage resolved in February 2025, the blanket justification that powered mass compounding is gone [1].
- What’s left is individual. A clinician can still determine that a specific patient has a specific medical reason for a compounded version, evaluated one person at a time rather than handed out automatically.
Think of it like a fire exit. It’s absolutely legitimate to use during an actual fire (the shortage). It is not meant to become your everyday front door once the fire’s out. That’s really the whole shift in one image.
Legality here depends on the presence of a real prescription, a genuine individual reason, and a licensed pharmacy playing by the rules. Take any one of those away, which is exactly what the gray market does, and you’ve left the “conditionally okay” zone entirely.
What about those no-prescription websites and “research use only” sellers?
Different question, and this one actually does have a clean answer: no.
Don’t let the nuance around legitimate compounding get smudged into this category, because they are not related. A site that ships you “semaglutide” with zero clinician, zero evaluation, and zero prescription is not doing patient-specific anything. And a seller labeling their product “research use only, not for human consumption” is telling you, in writing, that it isn’t meant to go in a human body. The instant that stuff gets marketed for people to actually use, it becomes an unapproved new drug, which is precisely the category the FDA is warning everyone about, counterfeits, false labeling, fake pharmacy names slapped on vials, all of it [1].
So picture two separate boxes. Box one: legitimate, prescription-based, individually-justified compounding, sitting in that conditional but real space. Box two: no-prescription sales and research-chemical listings, sitting entirely outside it, full stop. A lot of marketing works really hard to blur that line. Don’t let it.
Quick reality check: “legal” is not the same word as “safe”
This trips up more people than anything else on this page, so let’s slow down.
- Legal means: is this allowed under the rules.
- FDA-approved means: did the FDA actually review this exact product for safety, effectiveness, and quality before anyone got it.
- Safe for you means: is this drug, from this source, actually right for your body and your history.
A compounded batch can technically clear the legal bar (conditionally, individually) while still not being FDA-approved, and while still absolutely requiring careful screening to be safe for the person taking it. And that safety piece has real teeth, regardless of the legal answer. The approved Wegovy label carries a boxed warning for thyroid C-cell tumors and is a no-go for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [3]. That warning doesn’t care one bit whether your particular vial was compounded within the rules. It still needs to be checked, every time. On top of that, the FDA has reported actual dosing errors with compounded injectable semaglutide, people giving themselves five to 20 times the intended dose, some landing in the hospital, because compounded vials come in different concentrations and folks mixed up milligrams, milliliters, and units [4]. That’s a safety issue sitting completely apart from the legal question.
Honestly, this is why I think “is it legal” isn’t even the most useful thing to be asking. Even a fully above-board compounded prescription still needs a real clinician checking you against that label and watching your dose. Legal is the floor here, not the finish line.
So what does actually doing this responsibly look like?
A real prescription. A genuine individual reason a clinician can point to. A licensed pharmacy. And someone actually screening and following up with you, not a shortage technicality, not a no-questions-asked checkout page.
Given how much tighter the rules got, the responsible version of this looks like: a licensed clinician evaluates you, confirms there’s a real clinical basis, checks you against the label’s contraindications (including that thyroid warning [3]), writes a prescription if it’s appropriate, and a licensed pharmacy fills it. As one example of this actually being done properly, a telehealth provider like FormBlends operates on that model, clinician evaluation, real screening, a prescription when warranted, and dispensing through a licensed pharmacy, and they’re upfront that compounded semaglutide isn’t FDA-approved rather than pretending it’s just brand-name Wegovy in a different bottle. I’m mentioning them purely as one illustration of what the supervised, individually-justified pathway looks like in practice, not as a recommendation, not as a “buy here,” nothing for sale, no checkout, no claim that this bends any of the lines drawn above.
Here’s my honest bottom line for 2026. Compounded semaglutide isn’t illegal across the board, but the shortage-driven era that made it everywhere closed the moment the FDA declared that shortage resolved in February 2025 [1]. What’s left is narrower, individualized, still not FDA-approved [2], and legality by itself never replaces the real clinical screening a boxed-warning drug needs [3]. If someone tells you compounded semaglutide is just flatly “legal, same as Wegovy,” they’re mashing three separate questions into one and getting all three wrong.
The stuff people ask me right after this
Okay but what actually is semaglutide? It’s a prescription medication that copies a hormone your gut already makes naturally, called GLP-1. It started out approved for managing blood sugar in type 2 diabetes, then later got approved at a higher dose specifically for weight management. It’s a once-weekly injection sold under two brand names, Ozempic and Wegovy, and which one you get depends on what you’re treating and what dose you need.
Does it actually work for weight loss, or is this hype? It genuinely works, better than most weight-loss drugs that came before it. In the trials behind Wegovy’s approval, adults on the 2.4 mg weekly dose, combined with lifestyle changes, lost around 15 percent of their body weight on average over about 68 weeks. That number moves around a lot person to person, and most of the weight tends to come back if you stop taking it, so this is really a long-haul treatment, not a quick course.
Is semaglutide a “GLP-1”? Is that the same as Ozempic or Wegovy? Semaglutide is a GLP-1 receptor agonist, meaning it locks onto and activates the same receptor your body’s own GLP-1 hormone uses. Ozempic and Wegovy are both just brand names for semaglutide, approved for different uses and dosed differently. So when people casually say “GLP-1,” they usually mean the whole drug class. Technically, GLP-1 is the hormone itself, not the medication.
Is compounded semaglutide actually safe to use? Depends enormously on where it’s coming from. Semaglutide compounded by an FDA-registered pharmacy under physician supervision, the kind of setup a provider like FormBlends uses, goes through quality and sterility checks that random online sellers just do not bother with. The FDA has publicly warned about counterfeit and adulterated semaglutide sold outside legitimate medical channels. So who’s behind it, and who’s watching it, matters just as much as the actual molecule.
References
- FDA concerns with unapproved and compounded GLP-1 drugs used for weight loss, including the resolution of the semaglutide shortage (February 2025), counterfeits, and the fact that compounded versions are not reviewed for safety, effectiveness, or quality. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Compounding and the FDA: Questions and Answers. Compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed; FDA approval applies to finished products such as Wegovy and Ozempic, not to compounded preparations. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Wegovy (semaglutide) FDA-approved label: boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Novo Nordisk, DailyMed (FDA label).
- FDA alert on dosing errors with compounded injectable semaglutide: reports of patients administering five to 20 times the intended dose, some requiring hospitalization. U.S. Food and Drug Administration.
